BACKGROUND: Low ankle-brachial index (ABI) is a reflection of atherosclerotic disease, and high ABI is an indicator of calcified vessels. The associations of albuminuria and cystatin C level with incidence of either low or high ABI are unknown. STUDY DESIGN: Prospective longitudinal cohort study. SETTING & PARTICIPANTS: MESA (Multi-Ethnic Study of Atherosclerosis) enrolled community-dwelling adults (N=6,814) aged 45-84 years who were free of clinical cardiovascular disease at baseline. PREDICTORS: Baseline albumin-creatinine ratio (ACR) and serum cystatin C level. OUTCOMES: Development of low (<0.90), and high (>1.40) ABI using multinomial regression among persons with ABI of 0.90-1.40 at baseline. RESULTS: During 9.8 years of follow-up, 221 and 89 participants progressed to low and high ABIs, respectively. Baseline ACR and cystatin C level were higher among progressors compared with nonprogressors. In multivariable analyses, doubling of ACR was associated with increased risk of progression to low (OR, 1.08; 95% CI, 0.99-1.20) and high (OR, 1.16; 95% CI, 1.01-1.32) ABIs. Compared to the lowest quintile, the highest quintile of ACR had a significantly increased risk of progression to low (OR, 1.79; 95% CI, 1.03-3.12) and high (OR, 2.76; 95% CI, 1.32-5.77) ABIs. Higher cystatin C levels were associated with progression to low (OR per 1-SD greater, 1.12; 95% CI, 1.00-1.26) but not high (OR per 1-SD greater, 1.01; 95% CI, 0.81-1.25) ABI, but the highest quintile of cystatin C was not associated independently with either outcome. LIMITATIONS: Single measure of albuminuria and low number of progressors to high ABI. CONCLUSIONS: In adults free of clinical cardiovascular disease, albuminuria was a strong independent risk factor for the development of both high and low ABIs, important and different measures of peripheral artery disease.
BACKGROUND: Low ankle-brachial index (ABI) is a reflection of atherosclerotic disease, and high ABI is an indicator of calcified vessels. The associations of albuminuria and cystatin C level with incidence of either low or high ABI are unknown. STUDY DESIGN: Prospective longitudinal cohort study. SETTING & PARTICIPANTS: MESA (Multi-Ethnic Study of Atherosclerosis) enrolled community-dwelling adults (N=6,814) aged 45-84 years who were free of clinical cardiovascular disease at baseline. PREDICTORS: Baseline albumin-creatinine ratio (ACR) and serum cystatin C level. OUTCOMES: Development of low (<0.90), and high (>1.40) ABI using multinomial regression among persons with ABI of 0.90-1.40 at baseline. RESULTS: During 9.8 years of follow-up, 221 and 89 participants progressed to low and high ABIs, respectively. Baseline ACR and cystatin C level were higher among progressors compared with nonprogressors. In multivariable analyses, doubling of ACR was associated with increased risk of progression to low (OR, 1.08; 95% CI, 0.99-1.20) and high (OR, 1.16; 95% CI, 1.01-1.32) ABIs. Compared to the lowest quintile, the highest quintile of ACR had a significantly increased risk of progression to low (OR, 1.79; 95% CI, 1.03-3.12) and high (OR, 2.76; 95% CI, 1.32-5.77) ABIs. Higher cystatin C levels were associated with progression to low (OR per 1-SD greater, 1.12; 95% CI, 1.00-1.26) but not high (OR per 1-SD greater, 1.01; 95% CI, 0.81-1.25) ABI, but the highest quintile of cystatin C was not associated independently with either outcome. LIMITATIONS: Single measure of albuminuria and low number of progressors to high ABI. CONCLUSIONS: In adults free of clinical cardiovascular disease, albuminuria was a strong independent risk factor for the development of both high and low ABIs, important and different measures of peripheral artery disease.
Authors: A B Newman; L Shemanski; T A Manolio; M Cushman; M Mittelmark; J F Polak; N R Powe; D Siscovick Journal: Arterioscler Thromb Vasc Biol Date: 1999-03 Impact factor: 8.311
Authors: Holly Kramer; David R Jacobs; Diane Bild; Wendy Post; Mohammed F Saad; Robert Detrano; Russell Tracy; Richard Cooper; Kiang Liu Journal: Hypertension Date: 2005-06-13 Impact factor: 10.190
Authors: Ann M O'Hare; Anne B Newman; Ronit Katz; Linda F Fried; Catherine O Stehman-Breen; Stephen L Seliger; David S Siscovick; Michael G Shlipak Journal: Arch Intern Med Date: 2005 Dec 12-26
Authors: Michael H Criqui; Robyn L McClelland; Mary M McDermott; Matthew A Allison; Roger S Blumenthal; Victor Aboyans; Joachim H Ix; Gregory L Burke; Kaing Liu; Steven Shea Journal: J Am Coll Cardiol Date: 2010-10-26 Impact factor: 24.094
Authors: Helaine E Resnick; Robert S Lindsay; Mary McGrae McDermott; Richard B Devereux; Kristina L Jones; Richard R Fabsitz; Barbara V Howard Journal: Circulation Date: 2004-02-17 Impact factor: 29.690
Authors: Diane E Bild; David A Bluemke; Gregory L Burke; Robert Detrano; Ana V Diez Roux; Aaron R Folsom; Philip Greenland; David R Jacob; Richard Kronmal; Kiang Liu; Jennifer Clark Nelson; Daniel O'Leary; Mohammed F Saad; Steven Shea; Moyses Szklo; Russell P Tracy Journal: Am J Epidemiol Date: 2002-11-01 Impact factor: 4.897
Authors: R J Young; C C Macintyre; C N Martyn; R J Prescott; D J Ewing; A F Smith; G Viberti; B F Clarke Journal: Diabetologia Date: 1986-03 Impact factor: 10.122
Authors: Kunihiro Matsushita; Shoshana H Ballew; Josef Coresh; Hisatomi Arima; Johan Ärnlöv; Massimo Cirillo; Natalie Ebert; Jade S Hiramoto; Heejin Kimm; Michael G Shlipak; Frank L J Visseren; Ron T Gansevoort; Csaba P Kovesdy; Varda Shalev; Mark Woodward; Florian Kronenberg Journal: Lancet Diabetes Endocrinol Date: 2017-07-14 Impact factor: 32.069
Authors: Ravi V Shah; Matthew A Allison; Joao A C Lima; Siddique A Abbasi; Morgana Mongraw-Chaffin; Michael Jerosch-Herold; Jingzhong Ding; Matthew J Budoff; Venkatesh L Murthy Journal: J Nephrol Date: 2015-02-25 Impact factor: 3.902